Karma Biotechnologies

Karma Biotechnologies is a private U.S. biotech company developing antigen-specific immunotherapies for autoimmune diseases, allergies, and food sensitivities. The company describes its Xavine platform as a precision or tolerogenic immunotherapy approach intended to induce immune tolerance in vivo rather than broadly suppress the immune system. Its work appears to combine immunology with lipid nanoparticle engineering to create off-the-shelf therapeutics aimed at selectively silencing disease-causing immune responses. Publicly available information suggests the company remains at a preclinical stage, with no disclosed clinical-stage programs. Karma has raised seed financing from investors including SOSV and other early-stage backers.